АЛГОРИТМЫ МЕДИКАМЕНТОЗНОЙ ТЕРАПИИ КОРОНАВИРУСНОЙ ИНФЕКЦИИ (COVID-19) У ПАЦИЕНТОВ С УДЛИНЕНИЕМ ИНТЕРВАЛА QT



DOI: http://dx.doi.org/10.25298/2221-8785-2020-18-2-203-210


Л. В. Колоцей (L. V. Kalatsei), В. А. Снежицкий (V. A. Snezhitskiy), А. В. Ардашев (A. V. Ardashev)

Аннотация


С момента выявления первых случаев коронавирусной инфекции (COVID-19) не прекращается поиск эффективных препаратов для ее лечения. Наиболее перспективными в терапии COVID-19 стали противомалярийные, антиретровирусные препараты и антибиотики группы макролидов. Общий побочный эффект для данных групп препаратов – их способность к удлинению интервала QT и индуцированию пароксизмов полиморфной желудочковой тахикардии torsades de pointes, в особенности у пациентов с генетическими дефектами реполяризации миокарда желудочков. В настоящей статье представлены алгоритмы медикаментозной терапии пациентов с COVID-19 в зависимости от риска возникновения жизнеугрожающих желудочковых аритмий на фоне удлиненного интервалa QT, разработанные при поддержке Евразийской Аритмологической Ассоциации (EURA-3).


Ключевые слова


коронавирусная инфекция (COVID-19); гидроксихлорохин; интервал QT; полиморфная желудочковая тахикардия torsades de pointes

Полный текст:

Литература


In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). / X. Yao [et al.] // Clin Infect Dis. 2020. – ciaa237. doi:10.1093/cid/ciaa237 [опубликована онлайн 09.03.2020].

Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [published online ahead of print, 2020 Mar 9]. Clin Infect Dis. 2020;ciaa237. doi:10.1093/cid/ciaa237

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 / P. Colson [et al.] // Int J Antimicrob Agents. 2020. – 105932. doi:10.1016/j.ijantimicag. 2020.105932 [опубликована онлайн 04.03.2020].

Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 [published online ahead of print, 2020 Mar 4]. Int J Antimicrob Agents. 2020;105932. doi:10.1016/j.ijantimicag.2020.105932

Gao, J. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies / J. Gao, Z. Tian, X. Yang // Biosci Trends. 2020. – Vol. 4, №1. – P.72–73. doi: 10.5582/bst.2020.01047.

Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi: 10.5582/bst.2020.01047.

Clinical Characteristics of Coronavirus Disease 2019 in China. / W.J. Guan [et al.] // N Engl J Med. 2020; https:// doi.org/10.1056/NEJM oa2002032 [опубликована онлайн 28.02.2020].

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. [published online ahead of print, 2020 Feb 28] N Engl J Med. 2020; https:// doi.org/10.1056/NEJMoa2002032

SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. / C.I. Wu [et al.] // Heart Rhythm. 2020;S1547-5271(20)30285-X. doi:10.1016/j.hrthm.2020.03.024 [опубликована онлайн 31.03.2020].

Wu CI, Postema PG, Arbelo E, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes [published online ahead of print, 2020 Mar 31]. Heart Rhythm. 2020;S1547-5271(20)30285-X. doi:10.1016/j.hrthm.2020.03.024

Lazzerini, P.E. COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap! / P.E. Lazzerini, M. Boutjdir, P.L. Capecchi // Circulation. 2020; doi.org/10.1161/CIRCULATIONAHA.120.047293 [опубликована онлайн 14.04.2020].

Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap! [published online ahead of print, 2020 Apr 14] Circulation. 2020; doi. org/10.1161/CIRCULATIONAHA.120.047293

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. / M. Wang [et al.] // Cell Res. 2020. – Vol. 30, №3. – P.269–271. doi:10.1038/s41422-020-0282-0

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial / P. Gautret [et al.] // Int J Antimicrob Agents. 2020; doi: 10.1016/j.ijantimicag.2020.105949. [опубликована онлайн 20.03.2020].

Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20] Int J Antimicrob Agents. 2020; doi: 10.1016/j.ijantimicag.2020.105949

CredibleMeds [Electronic resource]. – Available from: https://crediblemeds.org. (accessed 14.04.2020).

СredibleMeds [Electronic resource]. – Mode of access: https://crediblemeds.org. – Date of access: 14.04.2020.

No proarrhythmic properties of the antibiotics moxifloxacin or azithromycin in anaesthetized dogs with chronic-AV block. / M. Thomsen [et al.] // Br J Pharmacol. 2006. – №149. – P.1039–1048.

Thomsen M, Beekman J, Attevelt N, Takahara A, Sugiyama A, Chiba K, et al. No proarrhythmic properties of the antibiotics moxifloxacin or azithromycin in anaesthetized dogs with chronic-AV block. Br J Pharmacol. 2006;149:1039–48.

Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice. / Y. Choi [et al.] // BioMed Research International. 2018. –№2018. – P.1–8. doi.org/10.1155/2018/1574806

Choi Y, Lim H-S, Chung D, Choi J, Yoon D. Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice. BioMed Research International. 2018;2018:1–8. doi.org/10.1155/2018/1574806

Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. / A.A. Fossa [et al.] // Am J Trop Med Hyg. 2007. – Vol. 77, №5. – P.929–938.

Fossa AA, Wisialowski T, Duncan JN, Deng S, Dunne M. Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. Am J Trop Med Hyg. 2007;77(5):929–38.

Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID-19: initial assessment. / N. Ford [et al.] // Journal of the International AIDS Society. 2020. – Vol. 23, №4. – e25489. doi: 10.1002/jia2.25489

Ford N, Vitoria M, Rangaraj A, et al. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID-19: initial assessment. Journal of the International AIDS Society. 2020;23(4):e25489. doi: 10.1002/jia2.25489

Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 / B. Cao [et al.] // N Engl J Med. 2020; DOI: 10.1056/NEJMoa2001282. [опубликована онлайн 18.03.2020].

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. [published online ahead of print, 2020 Mar 18] N Engl J Med. 2020; DOI: 10.1056/NEJMoa2001282.

Giant T–U Waves Precede Torsades de Pointes in Long QT Syndrome A Systematic Electrocardiographic Analysis in Patients With Acquired and Congenital QT Prolongation. / P. Kirchhof [et al.] // J Am Coll Cardiol. 2009. – Vol. 54, №2. – P.143–149. doi: 10.1016/j.jacc.2009.03.043.

Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T–U Waves Precede Torsades de Pointes in Long QT Syndrome A Systematic Electrocardiographic Analysis in Patients With Acquired and Congenital QT Prolongation. J Am Coll Cardiol. 2009;54(2):143–9. doi: 10.1016/j.jacc.2009.03.043.

Колоцей, Л.В. Синдром удлиненного интервала QT. Часть 2 / Л.В. Колоцей, В.А. Снежицкий // Журнал Гродненского государственного медицинского университета. – 2018. – Т.16, №5. – С. 533–541. doi: 10.25298/2221-8785-2018-16-5-533-541

Kolocej LV, Snezhickij VA. Sindrom udlinennogo intervala QT. Chast’ 2 [Long QT interval syndrome. Part 2]. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta [Journal of the Grodno State Medical University]. 2018;16(5):533–41. (Russian) doi: 10.25298/2221-8785-2018-16-5-533-541

AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram Part IV: The ST Segment, T and U Waves, and the QT Interval A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society Endorsed by the International Society for Computerized Electrocardiology / P. Rautaharju [et al.] // Journal of the American College of Cardiology. – 2009. – Vol. 53, №11. – Р. 982 – 991. doi: 10.1016/j.jacc.2008.12.014

Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, et al. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram Part IV: The ST Segment, T and U Waves, and the QT Interval A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53(11):982-91. doi: 10.1016/j.jacc.2008.12.014.

Колоцей, Л.В. Методологические подходы к измерению и оценке длительности интервала QT стандартной электрокардиограммы / Л.В. Колоцей, В.А. Снежицкий // Журнал Гродненского государственного медицинского университета. – 2019. – Т.17, №1. – С. 99–105. doi: 10.25298/2221-8785-2019-17-1-99-105

Kolocej LV, Snezhickij VA. Metodologicheskie podhody k izmereniju i ocenke dlitel’nosti intervala QT standartnoj jelektrokardiogrammy [Methodological approaches to measuring and estimating the duration of QT interval of a standard electrocardiogram]. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta [Journal of the Grodno State Medical University]. 2019;17(1):99–105. (Russian) doi: 10.25298/2221-8785-2019-17-1-99-105

Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19) / J.R. Giudicessi [et al.] // Mayo Clin Proc. 2020;doi:10.1016/j.mayocp.2020.03.024 [опубликована онлайн 07.04.2020].

Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19) [published online ahead of print, 2020 Apr 7]. Mayo Clin Proc. 2020;doi:10.1016/j.mayocp.2020.03.024

Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study / B. Charbit [et al.] // Anesthesiology. 2008. –№109. – Р.206–212.

Charbit B, Alvarez JC, Dasque E, Abe E, Démolis JL, Funck-Brentano C. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology. 2008;109:206–212.

Lengthening of cardiac repolarization in isolated guinea pig hearts by sequential or concomitant administration of two IKr blockers / R. Hreiche [et al.] // J Pharm Sci. 2011. – №100. – Р.2469–2481.

Hreiche R, Plante I, Drolet B, Morrissette P, Turgeon J. Lengthening of cardiac repolarization in isolated guinea pig hearts by sequential or concomitant administration of two IKr blockers. J Pharm Sci. 2011;100:2469–2481.

Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature / A.D. Meid [et al.] // Ther Adv Psychopharmacol. 2017. – Vol. 7, №12. – Р.251–264. doi:10.1177/2045125317721662

Meid AD, Bighelli I, Mächler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251–264. doi:10.1177/2045125317721662.

Development and validation of a risk score to predict QT interval prolongation in hospitalized patients / J.E. Tisdale [et al.] // Circ Cardiovasc Qual Outcomes. 2013. – Vol. 6, №4. – Р.479–487. doi:10.1161/CIRCOUTCOMES.113.000152

Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479–487. doi:10.1161/CIRCOUTCOMES.113.000152.


Ссылки

  • На текущий момент ссылки отсутствуют.